Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-11-29 am EST
0.6640 EUR   -6.74%
04:07pMDxHealth Provides Business Update
GL
04:07pMDxHealth Provides Business Update
GL
11/04European ADRs Move Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings

05/27/2021 | 04:59pm EST

NEWS RELEASE – REGULATED INFORMATION 

27 May 2021, 23:00 p.m. CET

IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM")

The items on the agenda of the AGM and EGM included the approval of a number of resolutions relating to the financial year ended on 31 December 2020, as well as the issuance of a new share option plan called the "2021 Share Option Plan" and the renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital. The proposed resolutions that were submitted to the meetings were all duly passed.

The minutes of the AGM and EGM, and documents that were submitted to the meetings can be accessed via the Company’s website.

About MDxHealth®

MDxHealth is a commercial-stage, innovative healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: 

twitter.com/mdxhealthfacebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information: 
MDxHealth
info@mdxhealth.com
 

Important information

The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA (the "Company" or "MDxHealth"). All other trademarks and service marks are the property of their respective owners.

This announcement contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of MDxHealth only as of the date of this announcement.

Attachment


Primary Logo


ę GlobeNewswire 2021
All news about MDXHEALTH SA
04:07pMDxHealth Provides Business Update
GL
04:07pMDxHealth Provides Business Update
GL
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
10/27MDxHealth SA Reaffirms Revenue Guidance for the Year 2022
CI
10/27MDxHealth SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
More news
Analyst Recommendations on MDXHEALTH SA
More recommendations
Financials
Sales 2022 40,9 M 42,3 M 42,3 M
Net income 2022 -33,9 M -35,1 M -35,1 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 108 M 112 M 112 M
Capi. / Sales 2022 2,65x
Capi. / Sales 2023 1,60x
Nbr of Employees 191
Free-Float 84,3%
Chart MDXHEALTH SA
Duration : Period :
MDxHealth SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,66
Average target price
Spread / Average Target -
Managers and Directors
Michael K. McGarrity Chief Executive Officer & Executive Director
Ron Kalfus Chief Financial Officer
Koen Hoffman Chairman
Miriam Reyes Executive Vice President-Operations
Joseph Sollee Chief Compliance Officer, EVP & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MDXHEALTH SA-24.72%120
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-24.68%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.20.76%25 738
SEAGEN INC.-24.08%22 506